Tag:

Doxil

Latest Headlines

Latest Headlines

J&J done with Boehringer plant after building a supply of Doxil

When Boehringer Ingelheim closed its troubled sterile manufacturing site in Ohio, which had been the sole supplier of Johnson & Johnson's ovarian cancer drug Doxil, J&J's Janssen unit worked out a deal to take over manufacturing of the bulk drug product for 6 months. Now, with at least a 9-month supply of Doxil in hand, that arrangement is over.

J&J builds 9-month supply of Doxil with creative problem solving

A Johnson & Johnson exercise in creative problem solving has paid off for doctors and patients who rely on its ovarian cancer drug Doxil, availability of which has been uncertain for years. Its Janssen unit has accumulated a significant supply after assuming manufacturing at Boehringer Ingelheim plant that otherwise was closed down at the end of the year.

FDA approves J&J to make bulk Doxil at closed Ben Venue plant

The FDA has now signed off on Janssen's process of manufacturing bulk Doxil at an Ohio facility. It is part of an "alternative manufacturing process" in which the company hands off fill and finish of the drug to another manufacturer.

UPDATED: J&J releases more Doxil, its popular cancer med that has been dogged by supply issues

Johnson & Johnson's Janssen, which has struggled to maintain ready supplies of its ovarian cancer treatment Doxil, has released a new lot of the popular drug. The injectable cancer med was produced through an "alternative manufacturing approach" in which the now-closed Ben Venue plant in Ohio made the bulk product and another manufacturer finished it off.

J&J seeks court's blessing to make Doxil at closed Ben Venue facility

Janssen and Ben Venue officials have assured a federal court that any operations Janssen initiates at Ben Venue's now-closed Ohio facility will comply with provisions of a consent decree that Ben Venue signed last year. The move came the same day that production officially ceased at the plant, which was the sole supplier of Doxil.

J&J moves forward with its plan to make Doxil in part of the closed Ben Venue plant

Boehringer Ingelheim stopped production at its Ben Venue Laboratories plant in Ohio this week, but now Janssen wants to lease the portion of the plant that made Janssen's ovarian cancer drug Doxil, which could relieve the shortage that has plagued the popular treatment since the FDA brought the hammer down on the plant two years ago.

UPDATED: J&J strikes a deal to manufacture Doxil itself at Ben Venue plant

Janssen Pharmaceuticals, which has struggled to maintain supplies of its cancer drug Doxil since supplier Ben Venue Laboratories ran into FDA issues, may have landed on a way to help keep supplies available. The Johnson & Johnson unit has an agreement to lease part of Ben Venue's Bedford, OH, plant and take on manufacturing itself.

Sun to benefit from Doxil shortage, but CEO eyes deals for bigger growth

With Johnson & Johnson's cancer treatment Doxil expected to run short till the end of 2014, India's Sun Pharmaceutical Industries stands to gain. To meet demand amid previous scarcity, the FDA allowed Sun's unapproved generic version of the drug to be imported into the U.S. Now, after a fast-track approval process, the drug has FDA's blessing, and Sun will have the market all to itself, at least for now.

Boehringer Ingelheim plant has become a money pit

After investing more than $350 million in upgrades, Boehringer Ingelheim has decided it is not worth continuing to pour money into its aging Ben Venue Laboratories plant in Bedford, OH, and will shut it down instead, canning the 1,100 people who work there.

UPDATED: J&J's Doxil shortage to last until at least end of 2014

The saga of the shortage of ovarian cancer drug Doxil has hit a new turning point, and not for the better. Johnson & Johnson has indicated it will have no supplies of the popular drug until at least the end of next year because its sole supplier is permanently closing the plant that makes it and it will be unable to get new suppliers approved for another 12 months or more.